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t,Jtgdw..isuudyfms lm&raentoesamlnewhetheruMc 
odde rekosed in lscbemk myocat~Bmn dscmam the coroaary 
vodar rosbtom aad attesma~ tire severlty of contnctllc and 
-- 
lkxckgrmmd. Endotbellam-derivsd reluiog factor, recently 
ldentlfle~l PI nitrk o!dfle* is n potent relaxant of awmmry sulootll 
irmwle. 
Marftosl. TIM loft sntedor descending coronary artery was 
tbmugb an -1 bypass Ink placed in tbe 
comfid rrtey In 56 opea chest dogs After lmodynamk otablli- 
sat&wemcludedtbisbypasstubetodecreasecoroaaryblood 
Bow to 0~0 U&d of tbe auml Bow. lbemufter, we maintalued a 
con-t txtrlmary perhlslnu pressare (40.9 * 3.1 mm Hgl. 
Rmalfs. Under is&es& eonditior4 the corouary arterkwenous 
dilkremes la nitrate and nit&e (end products of aitrk oxide) 
incmsDd (fkuuj.3 f 0.4 [mean + SEMI to 12.9 * 2.1 ~rol/Bter, 
p < 0.01). N%aomethyl L-arglnlae (3 ~qfbg bady weight per 
mkt, intncoronmy) decreased the coronary arterlavenour dltfer- 
cnces is nitrate sad nitrite (5.0 f 0.9 ~mobliter, p < 0.03) and 
corooary blood llow Worn 29.8 t 0.5 to 18.1 f 1.1 mUlOO g per 
mln, p < 0.091). Fractlooal sbortraing (from 3.7 f 1.0 IO -13 f 
iM%, p C 0.001) and lactate cntrac~ioa ratio (from -44.0 t 4.1 to 
-59.2 2 4.9%, p < 9.099) of the perfused area also decreased. 
These values were restored by the concomitant admlnistratton of 
~-ergkdue. Blood Bon to tbe endomyocordtam was decrensed 
relative to tbe eplmyocardium. A reduction la cotnnary blood Bow 
and wursenlng of myocardlal cotnractlle and metabolic fbacUons 
due to tbe administration of r&uoaometbyl Larglnlne daring 
hkmia were observed la denetvated Bearts. A reduction In 
coronary blood Bow In iscbemic myocardlum was observed wltb 
the adminlstratlon of Nw-EikO-MuginhIe methyl ester as we& 
although neither NW-nitro+arginlne methyl ester uor P- 
monometbyl Irargtnine changed comnary blood Bow and myocar- 
dial contractile and metabolle fuuctions in the nonkcltemk 
myocardlum. The cyclic guano&e monopbospbate content of 
rpkardlal coronary artery Increased due to myocardtal lschemiat 
this iacrease ~85 attenuated with uc-monometbyl Iraq&sine treat. 
meat. 
Conclusions, We couelude that edopnous q itrk oxide pre- 
dominantly deeteases the coronary vascular resistance of I!& 
emk endomyocardlum, thereby Improving q yomrdial contractil- 
Ity and metabolk function. 
(J Am Co8 Gwdiol1996;27:1804-12) 
In ischemic hearts, the coronary vascular resistance is mark- 
edly reduced to preserve myocardial perfusion via endogenous 
vasodilatory substances (l-3). Endothelium-derived relaxing 
factor is one of such substances, which induces potent coronary 
vasodilation (4). Recently, endothelium.derivcd relaxing fuctor 
has been identified as nitric oxide (5-7): several investigators 
have revealed that hypoxic- and ischemic-induced reactive 
hypercmic flow is partially mediated by nitric oxide (R-12). 
Park cl al. (9) have reported that hypoxia increases the release 
of nitric oxide in the rat myocardium, and Kostic and Schrader 
et al. (10) have demonstrated that N”-monomethyl L-arginine 
attenuates reactive hypercmic flow after a brief period of 
myocardial ischemia. These findings have been coafirmed by 
Yamabe et al. (II). Furthermore, Duncker and Rache (12) 
have shown that coronary blood flow during exercise in the 
hchemic heart is also attenuated by the administration of 
F;“nitro-I.-arginine. However, it has not been examined 
whether released nitric oxide improves myocardial perfusion in 
the irhemic myocardium due to coronary hypoperfusion and 
attenuate\ the severity of contractile and metabolic dysfunci 
lion. 
Tlrc present study was undertaken IO test the hypothesis 
that nitric oxide is released in the ishemic myocardium, 
decreasing ammary vascular resistance and deteriorating irr 
myocardii contractile and metabolic functions. We observe1 
the changes in coronary blood Bow and coronary arteriovenous 
differrtnccs in the end products of nitric oxide (nitrate and 
nitrite), ccben ~“4nunomethyl L-arginine (13) and t.‘-nitro 
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arginine methyl ester (14) were infused into the coronary 
artery. 
Methods 
Itimeotatka. Fifty-six mongrel dogs weighing 16 to 
24 kg were intravenously anesthetized with pentobarbital so- 
dium (30 m@kg body weight). Five days before the experimen- 
tal instrumentation, systemic chemical symplchectomy was 
performed in five dogs by intravenous injection of 50 m&g of 
6-hydroxydopamine (15,16). Deleterious side effects of 6-hy- 
droxydopamine were prevented by intravenous injectkms of 
propranolol (I mg/kg) and phentolamine (1 mg/kg). Three 
doses of 6- hydroxydopamine (10. 20 and 20 me/kg) were 
separately administered over a period of 24 h (15,16). 
The trachea was intubated and the dog was ventilated with 
room air mixed with oxygen. The chest was opened through the 
left fifth intercostal space, and the heart was suspended in a 
pericardial cradle. The proximal portion of the left anterior 
descending coronary artery was cannulated and perfused with 
blood through the left carotid artery through an extracorporeal 
bypass tube. Coronary perfusion pressure was monitored at the 
tip of the coronary arterial cannula, and coronary blood Row in 
the perfused area was measured with an electromagnetic Row 
probe attached at the bypass tube. A small, short collecting 
tube (l-mm diameter, 7 cm long) was inserted into a smail 
coronary vein near the center of the perfused area to sample 
coronary venous blood. The drained venous blood was coi- 
lected in a reservoir placed at the keel of the left atrium and 
returned through the jugular vein. To me.+surc myocardial 
regional fluw, the left atrium was c;umulated for the injection 
of microspheres. The femoral artery was also cannulated tor 
the sampling of reference (control) blood. Left ventricuiar 
pressure was measured by lise of a micromanometer (Konigs- 
berg P-S) placed thmugh the apex into the left ventricular 
cavity. A pair of ultrasound crystals were placed in the inner 
one third of the myocardium -1 cm apart to measure the 
myocardial xgment length witb an ultrasonic dimension gauge 
(Schuessler, 5 MHz). End-diastolic length was determined’at 
the R wave of the electrocardiogram, and end-systolic length 
was determined at the minimal dP/dt (17). Fractional shorten- 
ing was calculated by ([End-diastolic lcndhj - (End-systolic 
length])/(End-diastolic length) and served ds an index of 
myocardial contractility of the perfused area. 
L@nineonmpcawiiolhenwdyncunicandmetahulicvariablesin 
I& no&&mic mynwwkn, Five dogs were used in this pro- 
tocol. Coronary artcry and venous blood were sampled for 
blood gas analyst and determination of lactate concentrations. 
HemodymmGi hut&r& that is, kft ventricular pressure, 
dP/dt and segment length of tbe perfused area, were measured. 
The measuremen& were repealed 20 min after the onset of 
an infusion of tz”-wnometbyl I -arginine (3 and 30 ryncB per 
rain) into the coronary artery and 20 min after tbe discontin- 
uabnn of rs’-monontetbyl L-arginine. 
lktucol II: q@ts of ti’-munumet~ i.-afgihte and ~~-nihv 
a@nine methyl ester on myiwdal kkmdywk aad me&o& 
variables in the Memic mpcadium Forty-one doga were 
used in this protocol. After bemodynamic stabiliaation, wro- 
nary perfusion pressure was reduc4~J so that coronary blood 
How de-creased to one thii of the contrd tommy blood flow 
using an occluder attached at the extracorporeal bypass tube. 
After low coronary perfusion pressure was eat&ii the 
occluder was adjusted to keep coronary perfusiin pressure 
constant. All bemodynamic variabks were measured 1,3.5.7 
and 10 min after the onset of hypoperfusion. Both coronary 
arterial and venous blood samples were obtained at lO-min 
intervais for the measurement of lactate and norepinephrine 
concentrations and blood gas analysis. After these measure- 
ments, either N”-monomethyl t-arginine (3 &per min, n - 
11, the N”-monomelhyl L-arginine group) or L*-nitro erginine 
methyl ester (3 CLglkg per min. n = 5, the t.*-nitro arginine 
methyl ester group) was infused into the kft anterior descend- 
ing coronary artery. &cause Lv-nitro a&nine methyl ester has 
a potency to block the muscarinic receptors aside from a 
potency to inhibit the nitric oxide syntbase, we also tested the 
effects of N” monomethyl t-arginine on the ischemic hearts. 
Measurements of all hemodynamk and metabolic variables 
were repeated. Twenty minutes later, the infusiin of either 
N”-monomethyl L-argiome or L’-nitro arginii menethyl ester 
was discontinued, and hemodynamic and metabolic variabks 
were observ+zd until stabilization. Jn a preliminary study, we 
confirmed that these doses of ~~mmomethyl L-arginine and 
I’-nitro arginine methyl ester attenuate the coronary vasodi- 
latary capability of bradykinin by 82 z?z 5% and 87 It. 48, 
respectively, during a reduction in a>ronary perfusion ptes- 
sum. We also confirmed lbat the effects of N”-monomethyl 
L-arginhe and t”-nitro arginine methyi ester at a dosage of 
3 @kg per min were comparable with the effects of Nn- 
monomethyl L-arginine and L*-nitro arginine methyl ester at a 
dosage of M @kg prr min. Five dogs in the N”-mOnOnlethyi 
L-arginine pup were injected with microspheres inio the left 
atrium before and during coronary hypoperfusiin with and 
without N” monomethyl L-arginine. Endomyocardial and 
epimyocartiial tissues were sampled from these dogs IO assess 
the endocard;al-to-epicardial Bow ratio. We measured the 
concentration of nitrate and nitrite in coronary arterial and 
venous blood sampks obtained from live other dogs in the 
N”-monomethyl L-arginine group before and during the nduc- 
tion of coronary perfusion pressure with and without the 
administration of N~monornethyl L-arginine. We tested the 
effects of the vehicle for N“monomethyl I=arginine and L”- 
nitro arginine methyl ester (that is, saline solution) on COW 
nary blood flow in live other dogs during reduction of corona.? 
perfusion pressure.. 
To confirm the specitic effects of nitric oxide inhibitors on 
reductions in coronary blood flow, we tested 1) whether 
r-arginine cao reverse the decreases in coronary blood flow 
due to N”-monomethyJ L-a&nine administration, and 2) 
whe1be.r N”-monornethyl rrarginine can mimic the effects of 
k’-monomethyt r-arginine during coronary hypoperfusion. 
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ldcn~ical proccdurcs wcrc performed using I) N”+monomclhyl 
t..arginine (3 @g per min) and wqininc (4 &g per min) 
(n D 5, the N”-monomcthyl I.-arginine + t~arginine group). 
and2) n%nonomethyl o-arginine (3 &kgper min) alone (n = 
5, the N”-monomethyl n-arginine group) during coronary 
hypoperfusion. 
identical procedures and measurements were performed in 
five denervated dogs in experiments using N”-monomethyl 
t.-argiaine (3 @kgper min, the denervation group). We found 
that the myocardial norepinephrinc content in dcnervated 
(n = 5) and control (mnervated) dogs (n = 5) wcrc 25 + 4 and 
423 t 28 p@g (p < O.OOI), respectively. 
&uloeoi ill: efects of ,d’-monomerhyl /.-mginine on cfc%‘( 
guanosine monophosphale eonlent of epicdial conmary urterie.s 
in ischemic hear&. We investigated whether N”-monomethyl 
t-argininc reduces the cyclic guanosine monophosphate con- 
tent of epicardial artcries in the ischemic myocardium of IO 
dogs, With an occludcr attached to the extracorporeal bypass 
tube, coronary perfusion pressure was reduced so that coro- 
nary blood tlow decrcascs to one third of the control c;)ronary 
blood flow. After low coronary perfusion pressure was estab- 
lished, the occludcr was adjusted to keep coronary perfusion 
pressure at a constant low level. After maintaining low coro- 
nary perfusion pressure for 10 min, N”monomethyl I.-arginine 
(3 lcgn(gper min) was infuxd into the left anterior descending 
coronary artery for 20 min. Next, we removed rapidly the 
epicardial left anterior descending (ischemic region) and left 
circumflex (nonischcmic control region) coronary arteries (n = 
5) with prccoolcd scisw)rs and tongue and stored them in liquid 
nitrogen. Coronary perfusion prcssurc was reduced in live 
other dogs so that coronary blood flow dccrcased IO one third 
of the conlml coronary blood flow for 30 min; then, the 
epicardial left anrcrior dcrcnding (ischcmic region) and lclt 
circumllex (nonihchrmrc control region) epicardial “rronary 
artcries were removed rapidry and stored in liquid nitrogen. 
Chemb!rd mnlyslr. t:Jch coronary arterial ;Ind venous 
blood oxygen digercnce was assessed by determining the 
difference between coronary arterial and venous axvgen con- 
tents. Myocardial oxygen consumption (ml/IOU g per min) was 
calculated by coronary blood flow (ml/l00 g per min) X 
cordnary arterial and V~EOUS blood oxygen digcrcncc (ml/dl). 
Lactate conccntratzon ~a\ sqscsscd by the enzymatic assay 
(IS). bct;~lc extractiolr retie was obtained hy coronary artc- 
riovcnous dittercnccs in lactatc concentrations divided by the 
arterial lactate concentration and multiplrcd by limo. 
Norepinephrine ~asuremenr. l’hc method of norcpineph- 
rine mcasurcmcnt has been dcscrihcd pnriously (IO). Fivc- 
milliliter umplcs ol coronary rrtcrial and venous blood, 
collcrted into tubcw co:us,aining EDTA, were immcdiatclv 
placed in icsd water and centrifuged for 10 Tin. The pkr:.ma 
was then maintained al --w(PC. Within 2 weeks, plasma 
norcpinephrinc was absorbed onto alumina and separated 
using high-performance liquid chromatography (pump. LC- 
3A; culumn Zpax-SCX: Shimazu Scisakusho Co.). The plasma 
norepinephrinc conccntrlrtion was determined *ctrofluoro 
metrically by the trihydroxyindole method (Shimuu spec- 
trotluorophotometer RF-SOOLCA). 
Nitric ori& rn~asurcrrrcnr. The method of measuring nitric 
oxide has been described previously (20-22). Within 30 s after 
collection, heparinized blood was centrifuged for 5 min at 
2,OQ. The plasma fraction was then diluted with an equal 
amount of nitrite/nitrate-free distilled water. Then, 400 @I of 
diluted plasma was centrifuged at 2,OOOg with a micropore 
filter (Ultrafree MC Microcentrifuged Devil:e, UFC3, Milli- 
pore) to remove substances larger than 10 kDa. Filtered 
plasma was analyzed using an uutomated procedure based on 
the Gricss reaction (20-22). Briefly, nitrite within the sample 
was measured by its absorbance at 540 nm when mixed with the 
Gricss reagent, 0.1% of naphthylcthlcnediamide in 5% 
t(,,PO,. Absorbance at 540 nm was also measured after passing 
the samples through a copper-plated cadmium column for 
nitrate reduction; this value expressed the total amount of 
plasma nitric oxide end products (i.e., nitrate and nitrite). 
Cycttc guano&e monaphosphate meastumnetst. The meth- 
od of cyclic guanosine monophosphate measurements in 
tissues has been previously described (23-25). In brief, adven- 
titial connecrrve tissue (20 to 40 mg) was removed from the 
coronary arteries and stored at -80°C in liquid nitrogen. The 
frozen tissue was then powdered, homogemzed at 4°C in 1 ml 
of ice cold 6%’ trichloroacetic acid and centrifuged at 2.5OOg 
for 20 min. The supematant fluid was removed and extracted 
three times with 3 ml of diethyl ether saturated with water. 
The pr&ct was stored in the freezer at -80°C. The cyclic 
guanosir c monophosphate concentration in the super- 
natant fluid was mcasurcd using a radioimmunoassay 
method (23-25) within 7 days. Briefly, I(#) ~1 of a dioxunc- 
triethylamine mixture containing succinic acid anhydride suc- 
cis$atcd cyclic guanosine monophosphate in the supematant 
(IO0 ~1). After a IO-min incubation period, the reaction 
mixture was added to 800 ~1 cf 0.3 m&liter imidazole huger 
(pt I 6.5). One hundred microliters of succinyl cyclic ~uanosine 
monophosphate tyrosine methyl ester iodinated with iodine- 
I25 (15,000 to ZOJXH, counts/min in an amount less than IO- ” 
mol/!iter) was added to the assay mixture contaming IO0 r.d of 
the supernatant and I00 @I of dilured antisera in the presence 
of chloramiuc T (25). The mixture was kept at 4°C for 24 h. A 
cold solution ol dcxtran-coated charcoal (560 al) was then 
added to the mixture in an ice-cold water bath. The product 
was ccntrifupd (3,MDg), and 0.5 ml of the supernatant was 
counted for radioactivity in a gamma spcctromctrr. 
Measurements of regional coronary Hoad flow. Regional 
myocardial brood flow was determined using the microsphere 
tcrhniquc a+ prcvioualy rcportcd (26). Nonrrdioactivc micro- 
sphcrcs (Sckirui Plastic Co.. Ltd.), made of in& plaitic 
labelled with digcrcnt types of stabtc hctry elements. have 
been derribcd in detail in previous studuts (32). In the present 
sludy, micrtnphcrcs labelled wrth niobium. bromine, and rir- 
conium were used. Their mean diameter was 15 pm, and 
specific gravities were 1.32, 1.34 and 1.36, respectively. The 
microspheres were suspended in isotonic saline solution with 
ikttl’i Tween 840 to prevent aggregatron. The micm&~rcs 
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Talk I. Seywntial Changer in Systolic and Diastolic Blood Prteures and Heart Rate Before and 
During Coroaaty Hypoperfusion 
w GrmJP L&dine Before During wiial 
Sywlii hlcmd p-n (mm Hg) 
Nonisehemic (n = 9) 143 2 4 I42 r 2 138+2 143 t 2 
L-NMMA (n = 11) 140~4 143 r 4 14324 142 f 3 
L-NAME (n = 5) 144+4 I42 t 3 13823 IIC4 
c-NM?&4 (n = 5) 141 2 3 141 z 3 143 + 4 wt; 
L-NMMA 6 t.-arginine (n = 5) 140 f 4 142 - 4 142 + 5 141 t 4 
Denenininn (n 2 5) 141 t 6 b&r4 I3lZS 143Ll 
DimtolL b!wtl prcaure (mm Hg) 
Nunivhemic (n = 5) 82 2 1 II426 BP25 8427 
L-NMMA (II = II) n7*4 II7 t 4 iuro 84rr 
L-NAME (n = 5) MC ?I 5 nu f s RX?4 a t 5 
D-NMMA (n = S) RhtV ffl’h w2 ! 6 uz 1 a 
I.-NMMA t I.-argminc (n S) Ill ? 7 H4ZY 81 ? 9 Ul tY 
Dcnervalion (II - 5) Ho t Y 9o.t IU II5 L I0 79r9 
Heart rate (katslmin) 
Nnniackmic (n = 5) 147 + 2 14823 14ur4 I41 f. 3 
L-NMMA (n = It) I43 r 2 145 -c 2 144’-3 142 + 3 
L-NAME (n = 5) w-4 142 3 4 l43r4 I4454 
o-NM&l (n = 5) I41 % 3 I4013 143 r 4 l38?2 
I.-NMMA + L-arginine (n = 5) 14323 143 24 141 f 4 I4013 
Denewation (n = 5) 96 2 6t 93 L? 1t 95 + 7t 97 t lit 
‘V’A4onmthyl t-arginine (L-NMMA), L*-nitro arginine methyl ester (L-NAME), r+‘- mmmmeIhyl l%qliniine 
(o-NMMA)or o”-nitmarginine mrthylestcrhui*nonirfwmifeonditionorcomnuykypoprfudoo. tp< O.oUi VCMS 
the *-monomethyl I.-argininr group in each condilion. StatStkal significance was Ceskd by adpis ofwiance. Values 
are expressed as mean t SEM. 
were ultrasonicated for 5 min followed by 5 min of vortexing 
immcdiatcly before injection. Approximately 1 ml of the 
microsphere suspension (2 to 4 X ld spheres) was injected 
into the left atrium followed by several warm (37“C) saline 
flushes (5 ml). The microspheres were administered before 
,nd during coronary hypoperfusion with and without pharma- 
cologic interventions. Just before the administration of the 
spheres, a reference blood sample was obtained fmm the 
femoral artery at a constant rate of 8 mi/min over 2 min. 
pressure (105 t 2 and 102 f 3 from IO4 5 2 mm Hg) nor 
coronary blood flow (90.2 -+ 1.2 and 87.6 + 3.6 from 89.5 2 
2.4 ml/l00 g per mir) in the nonischemic myocardium. Sys 
tcmic hemodynamic variables (heart rate and systolic and 
diastolic pressure) were not changed by the administration of 
3 & per min of N”-monomethyl karginine (Table 1). 
The X-ray fluorescence activity of the stable heny &meats hypoperfusion, heart rate and systolic and diastolic pmsures 
was memured with a wavelength dispersive spectromctcr (PW were UM hanged with and withof:: pharmacologk interventkms 
1480, Phillips Co., Ltd.). Speck details of the functioning of (Table 1). Heart rate in the denervated heart was signilicantly 
this X-ray fluorescence spectrometer have been described pnzvi- reduced compared with the nondenervated heart; however, 
ow!y (26). The endocardium versus epicardium myocatdial blood heart rate dii not change during coronary hypoperfusion in the 
tlow ratio was calculated as the ratio d each t&e content denervated heart. Table 2 demonstrates no signilkant differ- 
normalized with the wet weight of sampled myocardium. cncc~ in hemodyn~mic and metabok variables before the 
Slntlstkal ardysie. Statistical analysis was performed hy onset of coronary hypoperfusion among all groups except the 
using analysis of variance (27.28). When analysis of variance dcnervated group. 
revealed significant differences, Bonfcrmni probabilities were Ten minutes after the reduction in coronary perfusion 
examined (28). Results are expressed as mean value 2 SEM; pressure, the differences in the nitrate and nitrite concentra- 
p < 0.05 was considered significant. tions between coronary venous and arterial blood increased 
Rt!SUlt!i 
from 35 2 0.4 to 12.9 ?Y 21 q&liter (n = 5. p C 0.01 by 
repeated mcawrcs analysis of variance), which was blunted 
EIeasdN~-~MFginineO3tbtcoraaVy~ by N”-monomclhyi L-argininc (5.0 2 0.9 pmdlliter. p < a.@ by 
~~~~~ - iQ IJK - m-r- repeated measures analysis of variance). Fqure 1 shows the 
‘-monornctbyl t.-arginine (3 and 30 Ire/kg repmentative tracing from the experiment in which an infu- 
per min, LraculuKous) changed neither CotoMlry pcrfubion sion of N”- mmsomethyl karginine decrea5ed coronary bkd 
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T&k 1. Haxline Ctrroner) Hcmwynamic ;md kkti~h~lic Variahle~ tkforc the Onset of Coronary Hypqxrfusion in Each Group 
..m-ye-~--- SW.- .I .-e---,-s -.-.-- ---.-.-?...--w.- 
(‘PP (-.: FS Mvtr, IkH NF(A) NW 
Umup (mm Ilg) 
--- .--_ --.----~-----.“EL 
(mIMWlp pa min) , ‘ i ) (mUdI) PIWI pww wml) tptimt) --- 
L-NMblA(n = II) 103: s “I.? c Il.9 25.1 2 I.1 h.h7 t 0.29 25.1 - 1.1 7.10 f I).02 7.41 z U,lII 37s 2 22 382+23 
L-NAME fn = S) los-‘4 31.9 f IU 2J.h 2 I.1 6.99 I! 0% 3.9 f ?.I 7.4lI fr 0.112 7.4u + fl.m 3R2 f 21 4lR 2 24 
o.NMMA (n = 5) IO2Z6 n9.h i ?.I 26.0 2 2.2 h.7X z 0.40 26.1 r- 0.9 7.41 + 002 7.4tJ t 0.02 359 + 19 39X~20 
L-NMMA + L-rrginiw IM?h Ye.3 r I.9 245 z I.9 b.llR f 0.28 25.7 f 22 7.41 4 0.01 7.39 c 0.02 377 2 16 4tmf Ill 
(a = 5) 
Lkncmrioc (ll = 5) 104rn rib.9 e 3.3’ 26s t 2.7 5.52 f 0.28 2S.3 t 0.h 7.41 t MII 7.40 + 0.01 459 + 27’ 4% It 39’ 
flow during coronary hypoperfosion. Twenty minutes after the 
onset of the N”-monomethyl I.-arginine infusion, both coronary 
blood flow and fractional shortening decreased. These data arc 
summarized in Figure 2. Although coronary perfusion pressure 
was kept constant (Fig. 2A). an intracoronary infusion of 
@-monomethyl L-arginine decreased both coronary blood flow 
(p < 0.091 by repeated measures analysis of variance) and 
fractional shortening (p i O.M)I by repeated measures analysis 
of variance). Reduction of corona9 perfusion pressure de- 
F&we I. Reprwniarivc rrcurd~ of cwonwy pafusion prc,sure 
(UP). left vcntwular prcuurc (LVP), first dvrrvelivc of left vcnlric- 
ular prcwue (dP/tll). qmenr lrngth (Sl.) and wonmy hltnd flow of 
the perfuwd arca (CBF) twfwc. during and rftcr the immcorotwy 
adminisrr&w of ~‘~~monome~hyl 1 -arpininr: (I..NMMA) durmg hype- 
perfusion. Reduced coronary perfusion prcswrc ;md nyrtemir hema. 
dyniimk wiahler wcrc \hhlr throughout this prortwl. 
creaacd the endocardium versus cpicardidm myocardial blood 
flow ratio (I.10 + 0.09 vs. O.XI + 0.03, p < O.(l5), and 
N”-monomethyl t.-arginine further decreased it to 0.71 t 0.04 
(p C 0.M). Figure 3 shows the changes in myocerdial oxygen 
consumption, lactate extraction ratio and pH in the coronary 
venous blood. These variables were decreased due to N”- 
monomethyl t.-arginine (p < 0.001 by repeated measures 
analysis of variance). The pH of coronary arterial blood did not 
change throughout this study (7.40 + 0.01). The intracoronaty 
infusion of N”-monomethyl t.-arginine did not change norepi- 
nephrine concentrations in coronary venous blood (382 + 23 
pmol/ml before &hernia, 378 f 19 pmol/ml IO min after the 
onset of coronary hypoperfusion, 371 + 15 pmohml 20 min 
after the onset of N”-monomethyl t,-arginine infusion during 
coronary hypoperfurion) with unchanged norepinephrine con- 
centration in coronary artery blood. When we administered the 
vehicle for N”-monomethyl r-arginine (salinej, coronary blood 
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F@aro 2. Changes in cotonatj petfusion ptessute (A). cotonuty Mood 
flow (B), and frtiional shonening (C) during the infusion and 
withdt rwai of W-monomethyl I.-atgininc (LNMMA) before and 
during coroxvy hypnpetftkm, ‘“htce IO 5 ndrl afkr the N’- 
monomethyl t:atginine infusion, coronary blooo Ilow gradually de- 
cteaseo (81, as did fractional shortening (C). The reduced coronary 
perfusion pressure was maintained at a constant level (A). ic = 
inttWtonary. 
flow did not change during coronary hypoperfusion (30.4 2 I. I 
vs. 29.6 t 1.3 m~lO0 g p& min (d =-hi) before and 20 min 
after the onset of saline infusion, n = 5). Changes due to 
N”-moFomethyl i.-atginine were prevented by the concomitant 
admimsttation of L-arginine (coronary blood flow: 30.2 t 0.7 
VI. 31.0 f 1.1 mm Hg (p = NS) before and 20 min after the 
onset of r,“-monomethyl L-atginine and L-atginine infusion). In 
turn. a 2O-min infusion 01 k’-monomethyl u-arginine neither 
decreased coronary blood Row not worsened myocatdial isch- 
emia (coronary bIti flow: 2V.X + tl.7 vs. 30.4 z !.I! eW?! ; 
pet min (p = NS) before and 20 min after the onset of 
N”-monomelhyl o-atginine infusion). Table- 3 represents the 
cellular basis of the effects of nitric oxide. without N”- 
monomethyl L-atginine treatment, myocardial ischemia (cots- 
nary perfusion pressure: 104.2 2 3.3 to 42.2 i: 1.9 mm Hg; 
coronary blood flow: 90.3 2 I .7 to 30.2 * 0.9 ml/l00 g pet min) 
increased the ~ntenl of cyclic guanosine monophOsphate of 
Dim relation between i&iWtion d r&r& o&la syathaaa 
Mdtle-maaiItcoronc~MoodBowiaiaebcmlenryecanliear. 
There is no clear consensus that nitric oxide is rcleaKd in 
tespnnse to &hernia and that it causes increases in coronary 
blood &xv. In the present study, we demonstrated that isch- 
pmia increases the end-products of nitric oxide and that the 
administration of nitric oxide synthase inhibitors reduces both 
nitric oxide end-ptodxts and cormuy blood flow in ischemic 
myocatdium and that deterioration of contractile and meta- 
bolic functions also occur under these conditions. These results 
suggest that nitric oxide released from ischemic myocatdium 
contributes to decreases in artonary vascular resistance, 
whereas nitric oxide does not play a maiot role in the regula- 
tion of coronary blood flow in the nonischemic myocardhun. 
Absence of coronary hcmodynamic and metabolii effects of 
N”monomethyl L-arginine under nonischemic conditions does 
not necessarily exclude the possibility that nitric oxide is 
released in nonischcmii myocardium and that it contnites to 
the regulation of coronary blood flow via other mechanisms 
(6). for example, an increased release of adenosine may 
compensate for the lwk of nitric oxide effect. Indeed, evidence 
has indkated that there is a contin- basal rekase of nit+ 
the epicardial coronary arteries (126 + 8 ~9, 70 2 7 fmol/mg 
protein in Ihe left &urn&x coronary aFry, p C 0.05 by 
analysis of variance and thii effect was blunted by treatment 
with N”-monomethyl L-arginine @!I -e 6 YS. 72 t 9 fmd/mg 
protein). L”-nitro arginioe methyl ester induced identicaI 
changes in coronary hemodyna& and qocar&i contra&e 
and metabolic variables in the iachemic myocar&um cumpared 
with the N”-monomethyl L-arginine group (Fig. 4). 
In the denervated heart. after the reduction in coronary 
perfusion pressure, myocardial contractile and metabolie func- 
bls deeteased (anonaty perfusion plzssure: 40.2 + 3.0 mm & 
wtonaly blond Ilow: 295 2 1.2 ttluloo g per Illit& ftraiod 
shortening; 66 2 1.1%; lactate extra&m ratio: -37.2 + 3m; 
myocardial m amsump&: 3.20 * 0.15 ml/loU g per n&t: 
pHinthecoronaryvenousbloodz7.25 9O.03,pHinthecoroq 
dttety blnolJ: 7.40 t 0.01) wmparal with the nonhscbrmic 
cmditiotl (Table 2). l\vcnty mhMes after the onset of an infusion 
of No-monomethyl L-m during ct3mmy hypoperhrsion; 
wroJuuybkodoowdecreasedattdmyocardiaihwdawors- 
enedsndmetaboliiftmctimde-4mdtoUtesameertentasin 
the nondenervdted myxxardium (Figs, 2 and 3): coromuy perhi- 
sionpressure44.4+3AmmHg@=NS);~bEoodBaw 
19.2~2lmVloOgpermin@~O.~1~fradional~ 
I.8 t 12% @ < 0.05); lactate exh;lction ratio -48.8 2 3.6% 
(p < 0.01); myocanlial oxygen consuWM 2.22~OZJlllVlODg 
petmin(p<:0.005);pHintheummaryvenousblocul72OtO.fi3 
(p < 0.05); pH in the coronary ;utety blond 7.40 ? 0.02 (p = NS) 
(all p sign&ant levrb dctetmincd by repeated messures analysis 
of variance). Twenty minutes after the discontinuation of I$- 
monomethyl L-atginine, all variables returned to theii baseline 
levels. 
Discussion 
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Slguro 3. Change:; in lactate extraction ratio (A), pH of coronary 
venous hhti (II) and myocardirl oxygen consumption (C) before and 
after the intracwunary infusion of N”-monomethyi L-a@inine (t-- 
NMMA) (3 rg/%g per min), and after withdrawal of N”-monomethyl 
t-erginine during myocardial ischemia. 
oxide in the heart (2Y.30). Because all of the corona9 vasodi- 
lato9 mechanisms appear to be fully exerted. inhibition of one 
of these important vasodilatory mechanisms in ischemic myo- 
cardium might decrease corona9 blood Row. Under such 
condition:, inhibition of nitric uxidt: s,niha~ may make it 
possible to test whether nitric otidc is released: inhibition of 
nitric oxide synthase decreases corona9 blood flow when nitric 
oxide is relcascd in the ischemic myocardium. In the present 
study, WC observed I) the occurrence of a marked increase in 
nitric oxide end-products in ischcmie mywardium, and that 2) 
inhibition of nitric oxide synthase by N”-monomethyl L- 
a&tine and Lw-nitro arginine methyl ester decreased corona9 
blood Row in the ischemic myocardium and reactive hyperemic 
flow after 20 s of coronary occlusion. These findings suggest 
that nitric oxide is released in ischemic myocardium and th”t it 
regulates corona9 blood flow. Furthermore, the present study 
suggests thrl nitric oxide decreases the endomyucardial coro- 
nary vascular rcsistrnce preferentially thrn the epimyocardial 
vascular resistancr in the ischcmic myocardium. Although 
thew observations are consistent with those in previous studies 
T&de 3. Changes in Qclic Guantainc Monophosphate 
Cbtccntralcon (InrrUm~ pwtcin) of the C.Wma~ Artery 
----I__----- _---l_l_ 
--._... -.- _ --- .-----_-. ._ _. . .I..I _... -!I!!EE 
LAD Area 
(H-12). none of these studies were performed with regional 
low corona9 flow-induced &hernia. 
In addition to the direct corona9 vasodilation caused by 
nitric oxide, II was necessary to consider other possibilities that 
explain the present observation that FF-monomethyl L-arginine 
and LW-nitro arginine methyl ester decrease corona9 blood 
flow in the ischemic myocardium: 
1. &monomethyl t.-arginine may have nonspecific vaso- 
constrictive effects. However, concomitant administration of 
L-arginine during infusion of N”-monomethyl L-arginine re- 
stored the decreases in corona9 blood Rex and myocardial 
contractile and metabolic dysfunctions. In addition, N”- 
monomethyl u-arginine did not affect corona9 blood flow 
during corona9 hypoperfusion, indicating that the actions of 
N”-monomethyl I.-arginine and L’“-nitro arginine methyl ester 
are related to nitric oxide. 
2. Evidence has suggested that nitric oxide itself has a nega- 
tive inotropic effect (31$2), which may reduce myocardial con- 
tractility and oxygen consumption in the ischemic region, result- 
ing in a decrease in corona9 blood flow. However, this 
mechanism is unlikely because if nitric oxide can directly reduce 
the myocardial energy requirements by a reduction in contractil- 
ity, both NC’-monomethyl L-arginine and ~~-nitro arginine methyl 
ester should hLl$e improved the myocardial metabolii function 
asx%sed by determining lactate extraction ratio and pH of 
corona9 vcwus blood. However. both N”-monomethyl L- 
arginine and L”-nitro arginine metbyl eater decreased lactate 
extraction ratio and pH in the corona9 venous blood (Fik 4). 
3. Nitric oxide has been reported IO reduce sympathetic 
neural activity (33) and to cause co&a9 vaaudilation by 
decreasing the release of norepinephrine from the presynaptic 
vesicles. However, in our experiment, a) u”-monomefhyl L- 
qinine administration during corona9 hypoperfusion did not 
increase the norepinephrine concentration in the corona9 
venous blood: and b) N”monomethyl L-argjnine still reduced 
corona9 bkxd fLnv in the irhemic mjucardium in the den- 
ervated heart. 
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4. Nitric oxide also has been reported to inhibit platelet 
aggregation (34,35). Thus, attenuation of the release of nitric 
oxide by the administrations of t+“-monomethyl t.-arginine and 
t’“-nitro argininc methyl ester should have induced platelet 
aggregatton and decreased coronaty blood flow in the ischemic 
myocardium. If this were the case, the withdrawal of k’- 
monomethyl t.-arginine and t”-nitro arginine methyl ester may 
not have restored the decrease in coronary blood flow. How- 
ever, in the present study, withdrawal of N”-monomethyl 
t-arginine and t”-nitro arginine methyl ester did rztore the 
decrease in coronary blood flow. 
5. lntracotonary infusions of either N”-monomrthyl I.- 
arginine or t.‘“-nitro arginine methyl ester may have the 
potential to close functional collateral vessels to the ischemic 
areas that may have further increased the severity of ischemia. 
We cannot deny this possibility. Taken together, the present 
results suggest that nitric oxide plays a major role in the 
prexrvation of coronary blood flow and of myocardial con- 
tractile and metabolic functions in the ischcmic myocardium. 
Pmthuphysbtogk mm&l dlalcai #tkwmce dpreoemt stmdy ht 
ioehomlc heart. There is ‘consensus that endothelial cells are 
major sources for the produrtion of nitric oxide (6,736). fn 
addition, nitric oxide is also released from the leulcocytes. 
coronary smooth muscle, and cardiomyocytes (37), all of which 
may produce nitric oxide in the ischemic heart. Although we 
have shcnvn that nitric oxide is released in the ischemic 
myoctirdium based on the results that N”-monomethyl L- 
arginine and t.“-nitro arginine methyi ester potently reduce 
amtary blood tlow in iscbcmic myowrdium, we have not 
FifprO 4 Ch’dIIQeS in coronary pW! :ShO pressun (A). corunary Mood 
6ow (BJ, fracttonal shortening (0, lactate extraction ratii (D), pH of 
coronary venous blood (E) and myocardial oxygen mmuqnkn (P) 
due to the intracoronary intiuiin of L’“-nitro arginine methyl ester 
(L-&L-nZ) (3 @kg per min. intracutanc~) during corenary hype 
clarified the source of released nitric oxide in ischemic myo- 
cardium. 
Several vasoactive substances oth+r than nitric oxide may 
contribute to coromry vasodilation in the ischemic heart. 
Adenosine has been reported to increase coronary blood Dow 
in ischemic myocardium (1.3). Pms@andms mediate the 
ischemia- and hypoxia-induced coronary vasod~lation. Park et 
al. (9) have repotted that nitric oxide, adenosme and vasodi- 
latory prostaglandim independently mediate coronary vasodi- 
lation in the hypoxic hearts. We have ako reported that the 
effect of u”-monomethyl t.-arginine during coronary hypoper- 
fusion are not abolished by the concomitant administration of 
S-phenyltheophylline (38); these results agree with the findings 
of Park et al. (9). 
In the patients with coronary artery dkeases, hypertension 
and hyperlipidemia. the capability of endothelial celk to 
release nitric oxide is thought to be attenuated (38-40). If thi 
occurq nitric oxide production in these patients may be 
attenuated and ischemia may be worsened. Therefore, it is 
important to incmase the capacity of nitric ox& production in 
these patients Angiotettsin converting enzyme inhibitors may 
incmase nitric oxide production becaus-: they have btett re- 
lRl2 IUTAKALE F.T AL 
(‘ORONAHV ttLW0 II.OW AN0 NO IN IS(‘tll:Mt(‘ MYOX‘ARDIL’M 
ported to inctexic u6Utmululiona of hr.+iinifl and nitric oxide 
(41,42). Although further s[u@ is necessary More the appli- 
c&m of our present rcsuhs IO clinicul saltings, lhc prescn~ 
study proposes the idea that cndothclial function contributes 
to the regulation of myocdrdial perfusion in the ischemic 
myocardium. 
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